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Abstract  
AIM: A multi - centre two years the long prospective open clinical study was conducted in five countries located in 
four different continents from May 2015 to evaluate the clinical safety and efficacy of Automatic Biofibre hair 
implant in male and female androgenetic alopecia. Biofibre®is a CE/TGA certified medical grade polyamide fibre 
suitable for implantation.  
MATERIAL AND METHODS: A total of 213 patients were enrolled in the study. Patients were assessed pre -
operatively by Hamilton scale grading and the percentage of scalp covered by hair. All the patients underwent 
Biofibre hair implantation by a standardised surgical technique followed by adequate post-operative care. Efficacy 
of the implant was evaluated by surgeons and patients bimonthly for the first year and trimonthly during the 
second year. Any adverse effects were recorded during these visits.  
RESULTS: At the completion of the study period, a total of 194 patients concluded the trial and the results were 
statistically evaluated. Both Hamilton scale grading and covered area percent improved at the end of the study, 
and subjective and objective evaluations revealed satisfactory results. Side effects were reported in only 18 cases 
(9.27%) which were easily controlled by either topical or systemic treatment in 8 to 10 days.  
CONCLUSION: Overall a successful result was noticed in 97.94% of patients with great psychological 
satisfaction. 
 
 
 
 
Introduction 
 
Clinical experience with synthetic hair 
implantation began in Japan in the ‘70s and rapidly 
spread all over the world as the correction of male 
pattern baldness has always been a much sought-
after cosmetic surgical procedure. However, various 
complications occurred due to the rampant use of this 
technique by non - qualified personnel, poor patient 
selection, unsterile operating conditions, and non -
biocompatible implant material [1]. Subsequently, in 
1983, an FDA ban was issued against the 
implantation of synthetic fibres, such as monoacrylic, 
polyacrylic, polyester and natural processed human 
hair [2], owing to the rising unpopularity for this 
procedure amongst various dermatologists and 
surgeons due to the many adverse outcomes 
encountered [3]. 
With the advancements in biomedical 
technology, many biocompatible inorganic materials 
have come up, which have been more successful and 
have resulted in many fewer complications. 
Subsequent studies from Europe focused on 
biocompatible synthetic fibres and a better technique 
of insertion with proper medical protocols was 
conducted to prevent complications such as 
secondary infection or inflammation [4]. Investigations 
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on suture materials revealed that a specific polyamide 
mixture resulted in fewer foreign body reactions. 
These medical-grade polyamides were therefore 
selected to develop a biocompatible fibre for scalp 
implantation, a human hair-like, melt dyed fibre 
suitable for human use (Biofibre®, Medicap srl, Italy).  
The UE in 1996 recognised the artificial hair 
implant technique as medical act and included 
artificial hair in the medical devices list, therefore 
submitting it all safety standard requirements [5, 6]. In 
the same year also Australian TGA approved artificial 
hair use by qualified doctors in suitable clinics. 
 
 
Materials and Methods 
 
Biofibre®is a sterile, inert, UV - resistant, 
highly bio - compatible, medical-grade polyamide fibre 
which is 0.08 - 0.09 mm thick and 160 - 460 mm long 
suitable for male and female implantation [7]. 
Approved colouring agents are incorporated 
at the molecular level during the liquid extrusion 
phase by creating a stable compound with no colour 
migration. Biofibre® hair is available in 13 colours, 
three different shapes (straight, wave, curly) and three 
different lengths (15 cm, 30 cm, 45 cm). The fibres 
can be washed and dried like natural hair, but they 
should not be bleached or permanently waved. One 
end of the fibre carries an open knot to anchor it to the 
scalp tissue and to allow fibrosis. The special 
reversible knot allows total fibre extraction in case of 
need with no residues in the scalp. Histological 
studies have shown that a keratin shield surrounds 
the implanted fibres facing bacterial introduction [8]. 
This study began in May 2015, and 213 patients were 
enrolled in the trial from five investigational centres in 
agreement with the principles of the Declaration of 
Helsinki. All patients signed an informed consent form 
and were included according to the following inclusion 
and exclusion criteria (Table 1). The patients came 
from 4 different continents to have trials, resulting in 
having different climate, habits and ethnicity. 
Table 1: Patient inclusion and exclusion criteria 
Patient inclusion and exclusion criteria 
Inclusion Criteria Exclusion criteria 
Age 25 to 65 psychological disorders 
Clinical diagnosis of androgenetic alopecia 
and grading with Hamilton scoring 
dermatitis or any dermatosis of the scalp 
Good general health without any other 
pathology of the scalp 
chronic metabolic disorders, 
immunodeficiencies, allergies 
Patients willing to return for follow up patients not willing to return for follow up, or 
with reduced therapeutic compliance 
Informed consent jobs where hygiene could not be guaranteed 
and maintained 
 
Demographic and anamnestic information 
was collected with special regards to previous medical 
or surgical treatments and any known allergies. All 
patients underwent a preliminary dermatological 
checkup followed by biochemical blood profiles. All 
patients were tested for hypersensitivity by implanting 
only 100 fibres as a test implant. If there were no 
hypersensitivity reported in six weeks, 500 - 1200 
fibres were further implanted per session at a gap of 
minimum three weeks till a satisfactory cosmetic result 
was obtained. 
A standard operative technique was used for 
all the patients in all the centres and a similar post- 
operative care was provided to avoid bias due to 
different operators. A special needle- containing 
automatic implanter was used to implant the fibre. 
This instrument allows the operator to reach the right 
depth in the scalp implanting the fibre until the knot 
reaches the galea capitis. The fibres were spaced at a 
minimum interval of 2 mm. Special attention and care 
were paid by the operating surgeon to avoid 
implanting two fibres at the same point and giving any 
traction to the implanted fibre to avoid displacement of 
the fiber superficially. Topical as well as systemic 
antibiotics were prescribed to all cases for the next 
seven days. In addition to this, all patients were asked 
to use an antiseptic shampoo on alternate days for 
seven days and avoid tar - based shampoos. 
The post - operative evaluation included: 
efficacy (as judged by Hamilton scale grading, 
covered area percent, surgeon and patient’s 
subjective evaluation) and safety (as judged by 
adverse events). Clinical examination and scalp 
hygiene assessment were done bimonthly for the first 
year and every three months for the second year. The 
additional assessment was also done in case of any 
adverse events. 
 
 
Results 
 
A total of 213 cases of different origins and 
ethnicities were enrolled in the study, out of which 194 
cases completed the trial. Only 19 cases underwent 
test implantation and were excluded from the study for 
the following reasons (three cases developed a 
hypersensitivity reaction to test implants, six patients 
opted out due to personal reasons, and ten cases 
were lost to follow up). 
Table 2: Patients with previous alopecia treatments. Is it 
possible to move this table under the relative text reference 
Topical treatments 91 patients (46.91%) 
Systemic treatments 24 patients (12.37%) 
Surgery 18 patients (9.28%) 
 
Male patients represented the majority of the 
study population: 165 men (85.05%) vs 29 female 
(14.95%). The average age was 42 (± 4.78), with an 
age range of 25 - 65 years, 133 patients (68.56%) had 
taken previous treatments for alopecia (Table 2): 
Food and/or respiratory allergies were 
detected in 19 subjects (9.79%). However, in these 
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patients, no hypersensitivities were reported to the 
test implants. The average number of implanted fibres 
was 2302 (SD2.805; size 200.9) ranging from 300 to 
16000.The average duration of pain and tenderness in 
the implant area was 2.3 days (SD 4.096; se 0.2933) 
ranging from 1 - 20 days. A diagrammatic comparison 
of the Hamilton scale grading before and after the trial 
showed dramatic improvement (Fig. 1) with the 
majority of the patients being in Hamilton grade II after 
implantation. 
 
Figure 1: Grey - before; black – after hair implantation 
 
Both subjective (physicians and patients’) and 
efficacy evaluation data which were recorded on a 
three-grade scale (1 = slight improvement, 2 = 
moderate improvement, 3 = marked improvement) 
showed moderate to marked improvement at the end 
of the study. Average patients, surgeons’ and efficacy 
evaluation grades were 2.54, 2.53, and 2.34 
respectively.  
Table 3: Paired T-test for Hamilton Scale Grading 
Paired T-test for Hamilton Scale Grading 
average grade before: 4.52 
average grade of 2.33 
t = 20. 823 
p < 0.0001 
 
Overall a successful result was noticed in 
97.94% of the patients with psychological satisfaction. 
Paired T-test for Hamilton Scale Grading and Covered 
Area Percent gave statistically significant results 
(Table 3, 4). 
Table 4: Paired T-test for Covered Area Percent 
Paired T-test for Covered Area Percent 
average % before: 61.5 
average % after: 85.3 
t = -23.3 
p < 0.0001 
 
An annual rate of 10.61% was noticed. 
Careful maintenance of post-operative scalp hygiene 
and use of appropriate products contributes to 
reducing the fall rate and recurrent folliculitis. These 
fibres were found safe in 90.73% of cases. Adverse 
events were clinically classified into three categories 
(insignificant, mild, and moderate) and were observed 
in only 18 cases (9.27%), (Table 5, Fig. 2a). 
Table 5: Complication rate in patients 
 No. of patients % 
Insignificant 2 1.03 
Mild 12 6.18 
Moderate 4 2.06 
 
Insignificant adverse events like fibre curling 
were observed in two cases (1.03%). Curling of the 
fibre is often caused by wrong products application 
and does not affect the scalp. 
a)           b)  
c)  
d)  
Figure 2: a) Complication; b) results; c) therapy; and d) results after 
hair implant therapy  
 
Mild side - effects comprising localised slight 
inflammation and infection were recorded in 12 cases 
(6.18%) which improved thanks to topical anti-
inflammatories and antibiotics with an average healing 
time of 10.8 days. Staphylococci (aureus and 
epidermoids), Streptococcus pyogenes, and 
corynebacteria (acnes and other strains) were the 
microbial species repeatedly grown in the cultures in 
these cases. Poor scalp hygiene, excessive 
perspiration, dirty headgears, secondary seborrhea, 
inadequate skin care were identified as the main risk 
factors. 
Moderate adverse events observed in four 
cases (2.06%) also required some fibre removal, 
when frank abscess or pustular inflammation were not 
controlled by topical and systemic therapy. In these 
cases, microbiological cultures revealed 
Staphylococcus aureus infection and systemic 
antibiotic therapy (teicoplanin 400 mg. daily, im) was 
added to the local treatment in order to control 
infections. No residual damage or permanent scarring 
was observed during the follow up period in any of 
these cases .In none of the cases did we record any 
further complications after healing (Fig. 2 b, c, d). 
The results of this clinical trial demonstrate that 
Biofibre® hair implantation provides satisfactory 
results in both male and female cases of androgenetic 
alopecia. Patients with psychological disorders, 
autoimmune diseases, immunodeficiencies, lack of 
personal hygiene have to be excluded [9][10]. 
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Before implantation After implantation 
  
 
 
 
 
  
  
Figure 3: Several patients before (left) and after hair implantation 
(right) 
 
Use of biocompatible hair implant fibres, 
modern automatic equipment, careful selection of 
patients, respect of pre - and post-implant protocol 
and correct after care are essential requirements to 
achieve the expected results. If the medical protocol 
indications are respected, this technique represents a 
safe and efficacious method to treat androgenetic 
alopecia with immediate aesthetic results providing 
immense psychological comfort [11][12][13] to the 
male and with particular attention to female patients 
[14]. Use of wrong substances, of unsuitable 
treatment and a lack of hygiene or correct after-care 
can compromise the expected result. If problems 
appear and can’t be successfully treated, a complete 
fibre removal is performed without residues [15][16]. 
The Biofibre hair implant procedure can also be 
performed in combination with other hair restoration 
techniques such as follicular unit hair transplantation 
to maximize final aesthetic result or in case of scarce 
donor - area [17][19]. It is also an appropriate 
technique to cover scalp scars such as post-burn and 
post-traumatic scars [20][21]. Several implant tests on 
alopecia total are and alopecia areata cases are 
taking place with encouraging results. 
 
 
References 
1. Hanke CW, bergfeld WF. Fiber implantation for pattern 
baldness. JAMA. 1979; 241:146-8. 
https://doi.org/10.1001/jama.1979.03290280026020 
2. Food and Drug Administration: Listing of banned devices, 
prosthetic hair fibers, Code of federal regulations, 21:895.101.  
3. Schwartz RS, Downham TF. Dangers of synthetic fiber 
implantation for male pattern baldness. Cutis. 1980; 25:491. 
PMid:6991215  
 
4. D'Ugo A., Hair implantation, the exact method to carry it out, 32° 
Congresso Brasileiro de Cirurgia Plastica, Brasilia, Brazil, 
November 11-15, 1995. 
 
5. Directive 93/42/EEC of the Council concerning Medical Devices. 
 
6. Universal Medical Device Nomenclature System, Prostheses, 
Hair, Universal Medical Device Code, 16611.  
7. Palmieri B, Griselli G, D'ugo A, Palmieri G, Salti G. Evaluation of 
polyamide synthetic hair. A long-term clinical study. Panminerva 
Med. 2000; 42(1):49-53. PMid:11019605  
 
8. Santiago M., Estudo histológico de couro cabeludo implantado 
com fibras artificiais de poliamida, XXXV Congreso Brasileiro de 
Cirurgia Plástica, Goiânia, BRAZIL. November 1-4, 1998. 
 
9. Brady G, Fukuta K, Santiago M, Shiell R. Synthetic Fibers in 
Hair Restoration: Potential Benefits, Patient Selection, Possible 
Complications, International Society of Hair Restoration Surgery, 
11th Annual Meeting, New York, USA, October 15-19, 2003. 
 
10. Rateb A. Twenty years experience with artificial hair insertion 
for the treatment of alopecia, 19th IMCAS international congress, 
Paris, France, 26-29 January 2017. 
 
11. Lotti T. Aesthetic Disability, SIME 38TH congress, 12-14 May 
2017, Rome, Italy.  
12. Franca K., Current and Emerging Therapies in Hair 
Transplantation and Hair Implants, Oxford Clinical Handbook, May 
2017. 
 
13. Ramos Et Al, Biofibre Hair Implant – Impact on the Quality of 
Life. Journal of Biological Regulators & Homeostatic Agents. 2016; 
30(Suppl 2):21-5. PMid:27373130  
 
14. Santiago M., Fiber Hair Restoration – A Surgical Option to 
Treat Female Pattern Baldness, International Society of Hair 
Restoration Surgery, 11th Annual Meeting, New York, USA, 
October 15-19, 2003. 
 
15. Perez Rangel R. Cabello Inorganico Biocompatible, 
 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
42                                                                                                                                                                                                  https://www.id-press.eu/mjms/index 
 
 
Dermatologia Cosmética , Texto Académico, I° edicion 2011, 
presentacion February 2012 in 8th WCOCD. 
16. Tchernev G, et al. Biofibre Hair Implant: What is New, What is 
True? JBRHA. 2016;30(Suppl 2):27-34. PMid:27373131   
17. Brady G. Cases without Hope – Innovative Solutions in Difficult 
Cases, International Society of Hair Restoration Surgery, 13th 
Annual Meeting, Sydney, Australia, August 24-28, 2005. 
 
18. Seery G. Hair Repair. ISHRS Hair Transplant Forum 
International. 2003; 13(1): 260-261.  
19. Careno N. Injerto de pelo: qué hacer cuando no hay pelo 
 
donante?, Jornadas Universitarias de la Asociacion de 
Dermatologia de Chile, Santiago, Chile, June 23, 2015. 
20. Rahoui M. Biofibre et Cicatrice de Brulure du cuir Chevelu, 6° 
Congres National Algérienne de Chirurgie Esthétique, 28-29 Avril 
2016, Alger, Algérie. 
 
21. Santiago M, Perez Rangel R, D'ugo A, Griselli G, Igitian G, 
Garcia Martin I, Nesheim GB, Saad Eddin U, Smith G, Brady GW, 
Chaker C. Artificial Hair Fiber Restoration in the Treatment of Scalp 
Scars. Derm Surg. 2007; 33(1):35-44. 
 
 
